Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: An Indian perspective

Gupta Sudeep, Chatterjee Sanjoy, Nigade Jagdish, Aggarwal Shyam, Singhal Manish, S. S. Alurkar, Kukreja Anil, B. K. Smruti, Nag Shona, Agarwal Amit, Agarwal Vijay, R. T. Chacko, Desai Chirag, Goswami Chanchal, Keechilat Pavithran, Patil Poonam, Prasad Krishna, Rajendranath Rejiv, R. R. Rao, T. P. SahooSingh Ashish, Singh Randeep, Srinivasan Sankar, Warrier Arun, Swarup Binay, Bhattacharya Priyanka, S. H. Advani

Research output: Contribution to journalReview article

Abstract

Human epidermal growth factor receptor 2 (HER2)-positive is an aggressive subtype of breast cancer and has historically been associated with poor outcomes. The availability of various anti-HER2 therapies, including trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (TDM-1), has remarkably improved the clinical outcomes in patients with HER2-positive metastatic breast cancer (mBC). However, there is a need to optimize treatment within this population, given the wide variability in clinical presentation. Additionally, geographical and socio-economic considerations too need to be taken into account. To clarify and collate evidence pertaining to HER2-positive metastatic breast cancer, a panel of medical and clinical oncologists from across India developed representative clinical scenarios commonly encountered in clinical practice in the country. This was followed by two meetings wherein each clinical scenario was discussed in detail and relevant evidence appraised. The result of this process is presented in this manuscript as evidence followed by therapeutic recommendations of this panel for management of HER2-positive mBC in the Indian population.

Original languageEnglish
Pages (from-to)368-379
Number of pages12
JournalIndian Journal of Medical and Paediatric Oncology
Volume39
Issue number3
DOIs
Publication statusPublished - 01-07-2018
Externally publishedYes

Fingerprint

Breast Neoplasms
Therapeutics
Population
India
Economics
human ERBB2 protein

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Oncology

Cite this

Sudeep, Gupta ; Sanjoy, Chatterjee ; Jagdish, Nigade ; Shyam, Aggarwal ; Manish, Singhal ; Alurkar, S. S. ; Anil, Kukreja ; Smruti, B. K. ; Shona, Nag ; Amit, Agarwal ; Vijay, Agarwal ; Chacko, R. T. ; Chirag, Desai ; Chanchal, Goswami ; Pavithran, Keechilat ; Poonam, Patil ; Krishna, Prasad ; Rejiv, Rajendranath ; Rao, R. R. ; Sahoo, T. P. ; Ashish, Singh ; Randeep, Singh ; Sankar, Srinivasan ; Arun, Warrier ; Binay, Swarup ; Priyanka, Bhattacharya ; Advani, S. H. / Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer : An Indian perspective. In: Indian Journal of Medical and Paediatric Oncology. 2018 ; Vol. 39, No. 3. pp. 368-379.
@article{4d924d89980d40cf97788427372ebdfd,
title = "Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: An Indian perspective",
abstract = "Human epidermal growth factor receptor 2 (HER2)-positive is an aggressive subtype of breast cancer and has historically been associated with poor outcomes. The availability of various anti-HER2 therapies, including trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (TDM-1), has remarkably improved the clinical outcomes in patients with HER2-positive metastatic breast cancer (mBC). However, there is a need to optimize treatment within this population, given the wide variability in clinical presentation. Additionally, geographical and socio-economic considerations too need to be taken into account. To clarify and collate evidence pertaining to HER2-positive metastatic breast cancer, a panel of medical and clinical oncologists from across India developed representative clinical scenarios commonly encountered in clinical practice in the country. This was followed by two meetings wherein each clinical scenario was discussed in detail and relevant evidence appraised. The result of this process is presented in this manuscript as evidence followed by therapeutic recommendations of this panel for management of HER2-positive mBC in the Indian population.",
author = "Gupta Sudeep and Chatterjee Sanjoy and Nigade Jagdish and Aggarwal Shyam and Singhal Manish and Alurkar, {S. S.} and Kukreja Anil and Smruti, {B. K.} and Nag Shona and Agarwal Amit and Agarwal Vijay and Chacko, {R. T.} and Desai Chirag and Goswami Chanchal and Keechilat Pavithran and Patil Poonam and Prasad Krishna and Rajendranath Rejiv and Rao, {R. R.} and Sahoo, {T. P.} and Singh Ashish and Singh Randeep and Srinivasan Sankar and Warrier Arun and Swarup Binay and Bhattacharya Priyanka and Advani, {S. H.}",
year = "2018",
month = "7",
day = "1",
doi = "10.4103/ijmpo.ijmpo_201_17",
language = "English",
volume = "39",
pages = "368--379",
journal = "Indian Journal of Medical and Paediatric Oncology",
issn = "0971-5851",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

Sudeep, G, Sanjoy, C, Jagdish, N, Shyam, A, Manish, S, Alurkar, SS, Anil, K, Smruti, BK, Shona, N, Amit, A, Vijay, A, Chacko, RT, Chirag, D, Chanchal, G, Pavithran, K, Poonam, P, Krishna, P, Rejiv, R, Rao, RR, Sahoo, TP, Ashish, S, Randeep, S, Sankar, S, Arun, W, Binay, S, Priyanka, B & Advani, SH 2018, 'Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: An Indian perspective', Indian Journal of Medical and Paediatric Oncology, vol. 39, no. 3, pp. 368-379. https://doi.org/10.4103/ijmpo.ijmpo_201_17

Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer : An Indian perspective. / Sudeep, Gupta; Sanjoy, Chatterjee; Jagdish, Nigade; Shyam, Aggarwal; Manish, Singhal; Alurkar, S. S.; Anil, Kukreja; Smruti, B. K.; Shona, Nag; Amit, Agarwal; Vijay, Agarwal; Chacko, R. T.; Chirag, Desai; Chanchal, Goswami; Pavithran, Keechilat; Poonam, Patil; Krishna, Prasad; Rejiv, Rajendranath; Rao, R. R.; Sahoo, T. P.; Ashish, Singh; Randeep, Singh; Sankar, Srinivasan; Arun, Warrier; Binay, Swarup; Priyanka, Bhattacharya; Advani, S. H.

In: Indian Journal of Medical and Paediatric Oncology, Vol. 39, No. 3, 01.07.2018, p. 368-379.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer

T2 - An Indian perspective

AU - Sudeep, Gupta

AU - Sanjoy, Chatterjee

AU - Jagdish, Nigade

AU - Shyam, Aggarwal

AU - Manish, Singhal

AU - Alurkar, S. S.

AU - Anil, Kukreja

AU - Smruti, B. K.

AU - Shona, Nag

AU - Amit, Agarwal

AU - Vijay, Agarwal

AU - Chacko, R. T.

AU - Chirag, Desai

AU - Chanchal, Goswami

AU - Pavithran, Keechilat

AU - Poonam, Patil

AU - Krishna, Prasad

AU - Rejiv, Rajendranath

AU - Rao, R. R.

AU - Sahoo, T. P.

AU - Ashish, Singh

AU - Randeep, Singh

AU - Sankar, Srinivasan

AU - Arun, Warrier

AU - Binay, Swarup

AU - Priyanka, Bhattacharya

AU - Advani, S. H.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Human epidermal growth factor receptor 2 (HER2)-positive is an aggressive subtype of breast cancer and has historically been associated with poor outcomes. The availability of various anti-HER2 therapies, including trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (TDM-1), has remarkably improved the clinical outcomes in patients with HER2-positive metastatic breast cancer (mBC). However, there is a need to optimize treatment within this population, given the wide variability in clinical presentation. Additionally, geographical and socio-economic considerations too need to be taken into account. To clarify and collate evidence pertaining to HER2-positive metastatic breast cancer, a panel of medical and clinical oncologists from across India developed representative clinical scenarios commonly encountered in clinical practice in the country. This was followed by two meetings wherein each clinical scenario was discussed in detail and relevant evidence appraised. The result of this process is presented in this manuscript as evidence followed by therapeutic recommendations of this panel for management of HER2-positive mBC in the Indian population.

AB - Human epidermal growth factor receptor 2 (HER2)-positive is an aggressive subtype of breast cancer and has historically been associated with poor outcomes. The availability of various anti-HER2 therapies, including trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (TDM-1), has remarkably improved the clinical outcomes in patients with HER2-positive metastatic breast cancer (mBC). However, there is a need to optimize treatment within this population, given the wide variability in clinical presentation. Additionally, geographical and socio-economic considerations too need to be taken into account. To clarify and collate evidence pertaining to HER2-positive metastatic breast cancer, a panel of medical and clinical oncologists from across India developed representative clinical scenarios commonly encountered in clinical practice in the country. This was followed by two meetings wherein each clinical scenario was discussed in detail and relevant evidence appraised. The result of this process is presented in this manuscript as evidence followed by therapeutic recommendations of this panel for management of HER2-positive mBC in the Indian population.

UR - http://www.scopus.com/inward/record.url?scp=85051852169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051852169&partnerID=8YFLogxK

U2 - 10.4103/ijmpo.ijmpo_201_17

DO - 10.4103/ijmpo.ijmpo_201_17

M3 - Review article

AN - SCOPUS:85051852169

VL - 39

SP - 368

EP - 379

JO - Indian Journal of Medical and Paediatric Oncology

JF - Indian Journal of Medical and Paediatric Oncology

SN - 0971-5851

IS - 3

ER -